These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11791890)

  • 1. In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report.
    Pelkonen O; Boobis AR; Gundert-Remy U;
    Eur J Clin Pharmacol; 2001 Nov; 57(9):621-9. PubMed ID: 11791890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental models for predicting drug absorption and metabolism.
    Alqahtani S; Mohamed LA; Kaddoumi A
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1241-54. PubMed ID: 23687990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Models to predict intestinal absorption of therapeutic peptides and proteins.
    Antunes F; Andrade F; Ferreira D; Nielsen HM; Sarmento B
    Curr Drug Metab; 2013 Jan; 14(1):4-20. PubMed ID: 21933113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.
    Jones CR; Hatley OJ; Ungell AL; Hilgendorf C; Peters SA; Rostami-Hodjegan A
    AAPS J; 2016 May; 18(3):589-604. PubMed ID: 26964996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.
    Cho HJ; Kim JE; Kim DD; Yoon IS
    Drug Dev Ind Pharm; 2014 Aug; 40(8):989-98. PubMed ID: 23981203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the potential role of intestinal first-pass metabolism for the prediction of drug-drug interactions: the role of PBPK modeling.
    Alqahtani S; Bukhari I; Albassam A; Alenazi M
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):625-634. PubMed ID: 29806951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSPR in oral bioavailability: specificity or integrality?
    Cabrera-Pérez MÁ; Pham-The H; Bermejo M; Álvarez IG; Álvarez MG; Garrigues TM
    Mini Rev Med Chem; 2012 Jun; 12(6):534-50. PubMed ID: 22587767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo and in situ approaches used to study intestinal absorption.
    Luo Z; Liu Y; Zhao B; Tang M; Dong H; Zhang L; Lv B; Wei L
    J Pharmacol Toxicol Methods; 2013; 68(2):208-216. PubMed ID: 23831587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral peptide delivery: Translational challenges due to physiological effects.
    Tyagi P; Pechenov S; Anand Subramony J
    J Control Release; 2018 Oct; 287():167-176. PubMed ID: 30145135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of physiologically based absorption models in drug discovery and development.
    Parrott N; Lave T
    Mol Pharm; 2008; 5(5):760-75. PubMed ID: 18547054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
    Feng B; Varma MV; Costales C; Zhang H; Tremaine L
    Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of physiologically-based gut absorption model for probabilistic prediction of environmental chemical bioavailability.
    Lin HC; Chiu WA
    ALTEX; 2023; 40(3):471-484. PubMed ID: 37158362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.
    Martinez MN; Amidon GL
    J Clin Pharmacol; 2002 Jun; 42(6):620-43. PubMed ID: 12043951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.